Blackrock Health Sciences Trust (BME) Peer Comparison
$46.28
As on 26-Aug-2026 16:00EDT
Market cap
$570 Mln
Revenue (TTM)
$-- Mln
P/E Ratio
7.7
P/B Ratio
1
Div. Yield
6.9 %
| Blackrock Health Sciences Trust (BME) | FS KKR Capital (FSK) | BlackRock Science and Technology Trust II (BSTZ) | Tri Continental Closed Fund (TY) | BlackRock Capital Allocation Trust of Beneficial Interest (BCAT) | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
570 | 3,291 | 2,089 | 1,892 | 1,649 |
Revenue ($ Mln) |
36 | 948 | 266 | 205 | 225 |
Net Profit ($ Mln) |
76.97 | -375.00 | 314.36 | 254.31 | 221.99 |
Net Margin (%) |
-- | -39.56 | -- | -- | -- |
RoE (%) |
11.51 | -6.75 | 20.33 | 13.09 | 13.39 |
Price to Earnings |
7.74 | -- | 6.56 | 7.24 | 7.50 |
Price-To-Book |
1.04 | 0.65 | 1.22 | 0.98 | 1.04 |
Income Statement ($ Mln)
| Blackrock Health Sciences Trust (BME) | FS KKR Capital (FSK) | BlackRock Science and Technology Trust II (BSTZ) | Tri Continental Closed Fund (TY) | BlackRock Capital Allocation Trust of Beneficial Interest (BCAT) | |
|---|---|---|---|---|---|
|
Operating Revenue
|
36.16 | 1,171.00 | 265.96 | 204.61 | 225.03 |
|
Cost of Revenue
|
5.63 | 356.00 | 20.58 | 8.19 | 1.43 |
|
Gross Profit
|
30.53 | 815.00 | 245.38 | 196.42 | 223.60 |
|
Operating Expenses
|
-46.46 | 235.00 | -69.41 | -57.89 | 1.61 |
|
Operating Profit (EBIT)
|
77.00 | 580.00 | 314.79 | 254.31 | 221.99 |
|
Other Income
|
-- | -- | -- | -- | -- |
|
Profit before Tax
|
76.97 | 23.00 | 314.36 | 254.31 | 221.99 |
|
Provision for Tax
|
-- | 12.00 | -- | -- | -- |
|
Profit after Tax (Net Income)
|
76.97 | 11.00 | 314.36 | 254.31 | 221.99 |
|
Minority Interest
|
-- | -- | -- | -- | -- |
|
Consolidated Profit
|
-- | 11.00 | -- | -- | -- |
Liabilities ($ Mln)
| Blackrock Health Sciences Trust (BME) | FS KKR Capital (FSK) | BlackRock Science and Technology Trust II (BSTZ) | Tri Continental Closed Fund (TY) | BlackRock Capital Allocation Trust of Beneficial Interest (BCAT) | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
568.30 | 5,849.00 | 1,717.10 | 1,982.80 | 1,595.29 |
|
Minority Interest
|
-- | -- | -- | -- | -- |
|
Non-Current Liabilities
|
1.83 | 7,880.00 | 18.50 | 2.44 | 93.32 |
|
Current Liabilities
|
-- | -- | 17.50 | 2.04 | 277.11 |
|
Total Liabilities
|
570.14 | 13,729.00 | 1,753.11 | 1,985.24 | 1,965.72 |
Assets ($ Mln)
| Blackrock Health Sciences Trust (BME) | FS KKR Capital (FSK) | BlackRock Science and Technology Trust II (BSTZ) | Tri Continental Closed Fund (TY) | BlackRock Capital Allocation Trust of Beneficial Interest (BCAT) | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
564.79 | 13,548.00 | 1,721.20 | 1,972.27 | 1,958.96 |
|
Current Assets
|
5.34 | 181.00 | 31.91 | 12.97 | 6.75 |
|
Total Assets
|
570.14 | 13,729.00 | 1,753.11 | 1,985.24 | 1,965.72 |
|
Total Debt*
|
0.89 | 7,634.00 | 17.50 | -- | -- |
|
Net Current Assets
|
-- | -- | -- | -- | -- |
Cashflow ($ Mln)
| Blackrock Health Sciences Trust (BME) | FS KKR Capital (FSK) | BlackRock Science and Technology Trust II (BSTZ) | Tri Continental Closed Fund (TY) | BlackRock Capital Allocation Trust of Beneficial Interest (BCAT) | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
-4.35 | 592.00 | -47.75 | -- | 329.51 |
|
Cash Flow from Investing Activities
|
37.30 | 236.00 | 324.34 | -- | -- |
|
Cash from Financing Activities
|
-54.59 | -679.00 | -256.13 | -- | -- |
|
Net Cash Inflow / Outflow
|
-- | -- | -- | -- | -- |
Ratios
Profitability Ratios
| Blackrock Health Sciences Trust (BME) | FS KKR Capital (FSK) | BlackRock Science and Technology Trust II (BSTZ) | Tri Continental Closed Fund (TY) | BlackRock Capital Allocation Trust of Beneficial Interest (BCAT) | |
|---|---|---|---|---|---|
|
ROCE (%)
|
11.50 | 0.08 | 20.17 | 13.09 | 13.39 |
|
ROE (%)
|
11.51 | 0.18 | 20.33 | 13.09 | 13.39 |
|
ROA (%)
|
11.45 | 0.08 | 18.21 | 13.07 | 11.41 |
|
EBIT Margin (%)
|
-- | -- | -- | -- | -- |
|
Net Margin (%)
|
212.86 | 0.94 | 118.20 | 124.29 | 98.65 |
|
Cash Profit Margin (%)
|
-- | -- | -- | -- | -- |
Growth Ratios
| Blackrock Health Sciences Trust (BME) | FS KKR Capital (FSK) | BlackRock Science and Technology Trust II (BSTZ) | Tri Continental Closed Fund (TY) | BlackRock Capital Allocation Trust of Beneficial Interest (BCAT) | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
0.50 | 0.05 | -0.03 | -0.36 | 0.14 |
|
EBIT Growth (%)
|
-- | -- | -- | -- | -- |
|
Net Profit Growth (%)
|
228.16 | -98.12 | 15.45 | -20.71 | 14.18 |
|
EPS Growth (%)
|
2.37 | -0.98 | -0.42 | -0.21 | -- |
|
Book Value Growth (%)
|
-- | -- | -- | -- | -- |
Valuation Ratios
| Blackrock Health Sciences Trust (BME) | FS KKR Capital (FSK) | BlackRock Science and Technology Trust II (BSTZ) | Tri Continental Closed Fund (TY) | BlackRock Capital Allocation Trust of Beneficial Interest (BCAT) | |
|---|---|---|---|---|---|
|
Price / Earnings
|
6.91 | 377.07 | 4.94 | 6.87 | -- |
|
Price / Book Value
|
0.94 | 0.71 | 0.91 | 0.88 | -- |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
6.85 | 17.44 | 4.90 | 6.87 | -- |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| Blackrock Health Sciences Trust (BME) | FS KKR Capital (FSK) | BlackRock Science and Technology Trust II (BSTZ) | Tri Continental Closed Fund (TY) | BlackRock Capital Allocation Trust of Beneficial Interest (BCAT) | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.00 | 1.31 | 0.01 | -- | -- |
|
Short term debt to equity ratio
|
-- | 0.00 | 0.01 | -- | -- |
|
Current Ratio
|
-- | -- | 1.82 | 6.37 | 0.02 |
|
Quick Ratio
|
-- | -- | -- | -- | -- |
|
Interest Coverage
|
-- | 1.05 | -- | -- | -- |
Operating Efficiency Ratios
| Blackrock Health Sciences Trust (BME) | FS KKR Capital (FSK) | BlackRock Science and Technology Trust II (BSTZ) | Tri Continental Closed Fund (TY) | BlackRock Capital Allocation Trust of Beneficial Interest (BCAT) | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
1.18 | 35.10 | 0.59 | 6.25 | -- |
|
Asset Turnover
|
0.05 | 0.08 | 0.15 | 0.11 | 0.12 |
|
Receivable days
|
8.20 | 122.27 | 1.18 | 21.00 | 18.07 |
|
Inventory Days
|
-- | -- | -- | -- | -- |
|
Payable days
|
22.88 | 100.03 | 249.67 | 102.43 | 59,183.92 |
|
Cash Conversion Cycle
|
-- | -- | -- | -- | -- |